Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Puma Biotechnology, Inc.NASDAQ: PBYI

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $19.8M rose 42.8% year over year, ahead of the +23.2% change in trailing-twelve-month research & development. Sequentially, it rose 17.5% from the prior quarter. Over 3 fiscal years it compounded at +5.9% a year.

Context

  • Research & development amounted to 27.2% of revenue in FY2025, up 3.3 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +42.8% holds above the trailing-twelve-month pace of +23.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.8M+17.5% QoQ
Last fiscal yearDec 2025
$62.07M+13.0% YoY
LTMMar 2026
$68M+23.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+42.8%——
1 year+13.0%——
3-year CAGR+5.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
62.07M USD
Year-over-year change
+13.0%
4-year CAGR
-3.6%

Research & Development vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +23.2% is the 2nd highest of 11, against a peer median of +2.3%.
  • Research & development amounts to 29.9% of revenue for PBYI, versus a peer median of 167.8%.
PBYI Competitors
Research & Development for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNGXTango Therapeutics, Inc.LTM Sep 2026$152.48M USD+14.3%+7.7%—
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M USD-19.9%-12.2%86.2%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$129.68M USD+5.2%+71.4%—
NUVBNuvation Bio Inc.LTM Jun 2026$128.85M USD+18.2%+9.4%75.8%
VSTMVerastem, Inc.LTM Mar 2026$123.67M USD+33.3%+31.4%249.4%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$116.62M USD-0.1%+21.2%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$68M USD+23.2%+5.9%29.9%
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M USD-19.6%+9.2%6022.3%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$30.06M USD-37.6%-19.5%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$19.63M CAD+4.7%+15.5%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥13.28M CNY-94.8%-61.3%—
Peer median (excluding PBYI) —+2.3%+9.3%167.8%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue253.16M228.03M235.64M230.47M228.37M
Cost of Revenue63.7M55.09M62.68M64.4M58.16M
Gross Profit189.45M172.94M172.96M166.06M170.21M
Gross Margin74.8%75.8%73.4%72.1%74.5%
Research & Development71.87M52.24M50.38M54.94M62.07M
Selling, General & Admin116.29M89.98M89.31M80.16M71.21M
Operating Expenses188.16M149.22M140.32M135.1M132.92M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
EBITDA(4.69M)21.89M47.52M48.08M53.34M
EBITDA Margin-1.9%9.6%20.2%20.9%23.4%
Operating Income1.29M23.72M32.64M30.97M37.3M
Operating Margin0.5%10.4%13.9%13.4%16.3%
Interest Income160K813K2.61M4.72M4.08M
Interest Expense12.81M11.59M13.33M12.45M6.62M
Other Income / Expenses(30.09M)(23.26M)(9.97M)(6.87M)(1.52M)
Income Before Tax(28.8M)457K22.67M24.1M35.78M
Pre-Tax Margin-11.4%0.2%9.6%10.5%15.7%
Income Tax Expense324K455K1.08M(6.18M)4.67M
Net Income(29.13M)2K21.59M30.28M31.11M
Net Margin-11.5%0.0%9.2%13.1%13.6%
EPS (Basic)(0.72)0.020.460.620.62
EPS (Diluted)(0.72)0.020.450.620.61
Weighted Avg Shares40.64M44.67M47.13M48.65M50.01M
Weighted Avg Shares (Diluted)40.64M44.93M47.55M49.1M50.65M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.